filings.toolsItem 1. Legal Proceedings
4K characters. Original on sec.gov · Markdown
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations as described in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 10-K”), including those described below (as of June 30, 2026, except where noted below). While it is not feasible to predict the outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.
In the 2025 10-K, Abbott reported that it is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis as a result of being administered Abbott’s preterm infant formula products. Abbott further reported in the 2025 10-K that in a Missouri state court trial held in July 2024, a jury awarded a plaintiff (“Gill”) $495 million in damages, and Abbott appealed the Gill verdict to the Missouri Court of Appeals in December 2024. In May 2026, the Missouri Court of Appeals affirmed the Gill verdict. Abbott stands by its products and the information it provided about them, and it is seeking review of the ruling from the Supreme Court of Missouri.
In the 2025 10-K, Abbott reported that six shareholder derivative lawsuits had been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States District Court for the Northern District of Illinois against certain of Abbott’s current and former directors and officers relating to Abbott’s manufacturing of certain powdered infant formula products. In June 2026, the court granted final approval of a settlement of this matter.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c)Issuer Purchases of Equity Securities
| Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | |||||||||||||||||||||||||
| April 1, 2026 - April 30, 2026 | 3,499,094 | (1) | $ | 92.742 | 3,499,094 | $ | 6,365,048,004 | (2) | |||||||||||||||||||||
| May 1, 2026 - May 31, 2026 | 3,600,000 | (1) | 84.174 | 3,600,000 | 6,062,022,204 | (2) | |||||||||||||||||||||||
| June 1, 2026 - June 30, 2026 | 4,500,000 | (1) | 91.743 | 4,500,000 | 5,649,179,754 | (2) | |||||||||||||||||||||||
| Total | 11,599,094 | (1) | $ | 89.695 | 11,599,094 | $ | 5,649,179,754 | (2) |
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.On October 11, 2024, the board of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time.
Previous: Item 4. Controls and Procedures · Next: Item 6. Exhibits